Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-117820
Filing Date
2025-05-12
Accepted
2025-05-12 16:30:00
Documents
22
Period of Report
2025-06-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A d895609ddef14a.htm   iXBRL DEF 14A 427191
6 GRAPHIC g895609g01a01.jpg GRAPHIC 207563
7 GRAPHIC g895609g02a01.jpg GRAPHIC 259075
8 GRAPHIC g895609g53n48.jpg GRAPHIC 138397
9 GRAPHIC g895609g81m36.jpg GRAPHIC 30980
10 GRAPHIC g895609g97e77.jpg GRAPHIC 148251
11 GRAPHIC g895609g98e42.jpg GRAPHIC 30980
  Complete submission text file 0001193125-25-117820.txt   2853084

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rntx-20241231.xsd EX-101.SCH 3528
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rntx-20241231_def.xml EX-101.DEF 2592
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rntx-20241231_lab.xml EX-101.LAB 2700
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rntx-20241231_pre.xml EX-101.PRE 1693
24 EXTRACTED XBRL INSTANCE DOCUMENT d895609ddef14a_htm.xml XML 92191
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38130 | Film No.: 25935306
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)